Cargando…
E-Cigarettes—a review of the evidence—harm versus harm reduction
The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968985/ https://www.ncbi.nlm.nih.gov/pubmed/35370428 http://dx.doi.org/10.1177/1179173X221087524 |
_version_ | 1784679162299023360 |
---|---|
author | Feeney, Susan Rossetti, Victoria Terrien, Jill |
author_facet | Feeney, Susan Rossetti, Victoria Terrien, Jill |
author_sort | Feeney, Susan |
collection | PubMed |
description | The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape pens, mods, and vaping. The growing use of ENDS, or e-cigarettes, in the US and globally across populations is dramatic. Although users may think that e-cigarettes are less harmful than combustible tobacco products, the evidence shows that there are known risks and harms for users. E-cigarettes have varying amounts of toxicants, nicotine, and carcinogens and put the user at risk for lung diseases and COVID-19 similar to smokers. Currently, most governing bodies have not approved e-cigarettes as a smoking cessation tool but do state if a person has failed conventional smoking cessation treatments that e-cigarettes used alone for the short term may help those to quit combustible tobacco and nicotine. A shared decision-making approach should be used when discussing e-cigarettes as a harm reduction tool. More studies and long-term data are needed to assess potential benefits and harms. What is known is that prevention efforts and policy are needed to avoid adolescents and other vulnerable populations from initiating tobacco or e-cigarette use. |
format | Online Article Text |
id | pubmed-8968985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89689852022-04-01 E-Cigarettes—a review of the evidence—harm versus harm reduction Feeney, Susan Rossetti, Victoria Terrien, Jill Tob Use Insights Review The World Health Organization estimates there are 1.1 billion cigarette smokers across the globe and that tobacco related deaths number 7 million per year. Electronic nicotine delivery systems (ENDS) are available to contribute options for smoking cessation and include e-cigarettes, e-hookahs, vape pens, mods, and vaping. The growing use of ENDS, or e-cigarettes, in the US and globally across populations is dramatic. Although users may think that e-cigarettes are less harmful than combustible tobacco products, the evidence shows that there are known risks and harms for users. E-cigarettes have varying amounts of toxicants, nicotine, and carcinogens and put the user at risk for lung diseases and COVID-19 similar to smokers. Currently, most governing bodies have not approved e-cigarettes as a smoking cessation tool but do state if a person has failed conventional smoking cessation treatments that e-cigarettes used alone for the short term may help those to quit combustible tobacco and nicotine. A shared decision-making approach should be used when discussing e-cigarettes as a harm reduction tool. More studies and long-term data are needed to assess potential benefits and harms. What is known is that prevention efforts and policy are needed to avoid adolescents and other vulnerable populations from initiating tobacco or e-cigarette use. SAGE Publications 2022-03-29 /pmc/articles/PMC8968985/ /pubmed/35370428 http://dx.doi.org/10.1177/1179173X221087524 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Feeney, Susan Rossetti, Victoria Terrien, Jill E-Cigarettes—a review of the evidence—harm versus harm reduction |
title | E-Cigarettes—a review of the evidence—harm versus harm reduction |
title_full | E-Cigarettes—a review of the evidence—harm versus harm reduction |
title_fullStr | E-Cigarettes—a review of the evidence—harm versus harm reduction |
title_full_unstemmed | E-Cigarettes—a review of the evidence—harm versus harm reduction |
title_short | E-Cigarettes—a review of the evidence—harm versus harm reduction |
title_sort | e-cigarettes—a review of the evidence—harm versus harm reduction |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968985/ https://www.ncbi.nlm.nih.gov/pubmed/35370428 http://dx.doi.org/10.1177/1179173X221087524 |
work_keys_str_mv | AT feeneysusan ecigarettesareviewoftheevidenceharmversusharmreduction AT rossettivictoria ecigarettesareviewoftheevidenceharmversusharmreduction AT terrienjill ecigarettesareviewoftheevidenceharmversusharmreduction |